Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma

Overview of attention for article published in BMC Cancer, September 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter: 3 tweeters

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 15 Mendeley

Summary Twitter Dimensions citations

So far, Altmetric has seen 3 tweets from 3 users, with an upper bound of 3,800 followers.

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma https://t.co/eObEkIQCJL

14 Sep 2022

Reply Retweet Favourite

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma #lymphoma #lymsm https://t.co/S329huedo0

11 Sep 2022

Reply Retweet Favourite

New article: Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma https://t.co/g9msQ5WjBo #DLBCL #lymsm #hematology https://t.co/1dcKPIzml6

11 Sep 2022

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity.